Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study includes treating patients with atrial fibrillation (AF) with Dabigatran, an
anti-coagulant for a period of one year to see if there are any significant changes in the
degree of left atrial structural remodeling in these patients. The investigators hypothesize
that there will be a significant decrease in the degree of left atrial structural remodeling
(fibrosis) in AF patients treated with dabigatran.